David Cescon
University Health Network, Princess Margaret Hospital, Toronto ON Canada · University Health Network, PMH, Toronto ON · Princess Margaret Cancer Centre
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name David Cescon as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 10:16 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT05601440 · Liquid-biopsy Informed Platform Trial to Evaluate CDK4/6-inhibitor Resistant ER+/HER2- Metastatic Breast CancerCanadian Cancer Trials Group · recruiting · Breast Cancer · study chair
- Ph2NCT04176848 · CFI-400945 and Durvalumab in Patients With Advanced Triple Negative Breast CancerCanadian Cancer Trials Group · active not recruiting · Breast Cancer · study chair
- N/ANCT03740503 · Genomic Investigation of Unusual RespondersUniversity Health Network, Toronto · recruiting · Cancer, Breast Cancer, Non-small Cell Lung Cancer · principal investigator
- Ph2NCT03624543 · CFI-400945 in Patients With Advanced/Metastatic Breast CancerCanadian Cancer Trials Group · active not recruiting · Breast Cancer · study chair
- N/ANCT02732860 · Personalized Patient Derived Xenograft (pPDX) Modeling to Test Drug Response in Matching HostUniversity Health Network, Toronto · recruiting · Colorectal Neoplasms, Colorectal Cancer, Breast Cancer · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 10:16 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name in breast cancer, ranked by citations from NIH iCite, fetched 2026-11-12 10:16 UTC. The ranking covers the 200 most relevant of 16 PubMed records, and a shared surname and initials can bring in a namesake. All 16 on PubMed
- 1,567 citationsRCR 65.6
- Pembrolizumab plus Chemotherapy in Advanced Triple-Negative Breast Cancer.N Engl J Med · 20221,056 citationsRCR 72.2
- Pembrolizumab monotherapy for previously treated metastatic triple-negative breast cancer: cohort A of the phase II KEYNOTE-086 study.Ann Oncol · 2019696 citationsRCR 24.2
- 548 citationsRCR 19.1
- 193 citationsRCR 45.2
- Pembrolizumab and chemotherapy in high-risk, early-stage, ER+/HER2- breast cancer: a randomized phase 3 trial.Nat Med · 2025139 citationsRCR 29.7
- 88 citationsRCR 3.3
- Sacituzumab Govitecan plus Pembrolizumab for Advanced Triple-Negative Breast Cancer.N Engl J Med · 202674 citationsRCR 37.0
- An open-label, phase II multicohort study of an oral hypomethylating agent CC-486 and durvalumab in advanced solid tumors.J Immunother Cancer · 202060 citationsRCR 2.0
- 24 citationsRCR 12.0